Table 1.
Characteristic | HC | CD | UC |
---|---|---|---|
n | 23 | 11 | 18 |
Male/female | 13/10 | 4/7 | 12/6 |
Median age [95% CI] at sampling | 51.5 [41–57] | 43 [28–57] | 53.5 [47–60] |
Median age [95% CI] at diagnosis | 26 [18–47] | 35 [29–42] | |
Inflammation: endoscopic subscores for UC: | |||
Mayo 0 | 8 | ||
Mayo 1 | 3 | ||
Mayo 2 | 6 | ||
Mayo 3 | 1 | ||
IBD medications at sampling: | |||
Aminosalicylates | 4 | 15 | |
Azathioprine/6-mercaptopurine | 4 | 1 | |
Buscopan | 1 | 0 | |
Adalimumab | 1 | 0 | |
None | 4 | 3 | |
Non-IBD medications at sampling: | |||
Metformin/gliclazide/statin | 0 | 2 | |
Ondansetron | 1 | 0 | |
Certirazine | 1 | 0 | |
None | 9 | 16 |
Demographic and clinical data analysed in Figures 2, 4d, and Supplementary Figure S1, available as Supplementary data at ECCO-JCC online.
HC, healthy controls; CD, Crohn’s disease; UC, ulcerative colitis; CI, confidence interval.